Catalyst Net Interest Income from 2010 to 2026
| CPRX Stock | | | USD 23.23 -0.16 -0.68% |
Catalyst Pharmaceuticals' shows a recovering structural trend supported by multi-year data. Analyst models indicate potential upside toward approximately 26
M. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.
View All Fundamentals Net Interest Income | First Reported 2010-12-31 | Previous Quarter 24.8 M | Current Value 26 M | Quarterly Volatility 8.5 M |
Macro event markers
Credit Downgrade | Yuan Drop | Covid | Interest Hikes |
provides competitor comparison context for Catalyst Pharmaceuticals. The view supports competitor context.
Our
How to Buy Catalyst Stock guide explains the steps to invest in Catalyst Pharmaceuticals stock.
Analyzing Catalyst Pharmaceuticals's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing Catalyst Pharmaceuticals's current valuation and future prospects.
Latest Catalyst Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Catalyst Pharmaceuticals over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Catalyst Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend | | |
Catalyst Net Interest Income Regression Statistics
| Arithmetic Mean | 5,359,713 |
| Geometric Mean | 1,545,416 |
| Coefficient Of Variation | 158.30 |
| Mean Deviation | 5,970,954 |
| Median | 1,291,651 |
| Standard Deviation | 8,484,218 |
| Sample Variance | 72T |
| Range | 25.7M |
| R-Value | 0.78 |
| Mean Square Error | 30.3T |
| R-Squared | 0.60 |
| Significance | 0.0002 |
| Slope | 1,306,594 |
| Total Sum of Squares | 1151.7T |
Catalyst Net Interest Income History
| 2026 | 26 M | |
| 2025 | 24.8 M | |
| 2024 | 16.1 M | |
| 2020 | 4.7 M | |
| 2019 | 1.6 M | |
| 2018 | 1.3 M | |
| 2017 | 454.2 K | |
Stock Overview, Methodology & Data Sources
Catalyst Pharmaceuticals is scheduled to announce its earnings this week.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. As a large-cap equity, Catalyst Pharmaceuticals is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 23.62, P/B of 2.99, profit margin of 36.39%. Catalyst Pharmaceuticals has a market cap of 2.86 B, P/E of 23.62, ROE of 25.49%.
Methodology
Unless otherwise specified, financial data for Catalyst Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Catalyst (USA Stocks:CPRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Catalyst Pharmaceuticals is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, HSBC Global Research, Raymond James, Bernstein Research, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial Board
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
More Resources for Catalyst Stock Analysis
Reviewing Catalyst Pharmaceuticals commonly begins with
financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends.
Selected reports below provide context for Catalyst Stock: Catalyst Pharmaceuticals Correlation provides competitor comparison context for Catalyst Pharmaceuticals. The view supports competitor context.
Our
How to Buy Catalyst Stock guide explains the steps to invest in Catalyst Pharmaceuticals stock.
Analysis related to Catalyst Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the
Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Quarterly Earnings Growth -0.06 | Earnings Share 1.68 | Revenue Per Share | Quarterly Revenue Growth 0.076 | Return On Assets |
Investors evaluate Catalyst Pharmaceuticals using market value and book value, each describing different facets of the business. Catalyst Pharmaceuticals' market capitalization is 2.86 B. A P/B ratio of 2.99 indicates the market values Catalyst Pharmaceuticals above its accounting book value. Enterprise value stands at 2.15 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Catalyst Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Catalyst Pharmaceuticals, key inputs include a P/E ratio of 23.62, a P/B ratio of 2.99, a profit margin of 36.39%, and ROE of 25.49%. Trading price represents the transaction level agreed by market participants.